RecruitingNCT07441499

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Sponsor

Tianjin Medical University Second Hospital

Enrollment

300 participants

Start Date

Mar 1, 2026

Study Type

OBSERVATIONAL

Conditions

Urothelial Carcinoma (UC)Bladder (Urothelial, Transitional Cell) Cancer Liquid Biopsy

Summary

Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using liquid biopsy — a simple blood test that detects cancer DNA — to identify, track, and predict recurrence in people with urothelial carcinoma, a type of cancer that affects the bladder and urinary tract. Researchers want to see if this blood test can catch signs of cancer returning before symptoms appear. **You may be eligible if...** - You have suspected or confirmed urothelial carcinoma (bladder or urinary tract cancer) **You may NOT be eligible if...** - You have or have had another type of cancer that is currently active Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMulti-Component Liquid Biopsy for Urothelial Carcinoma

This intervention is a non-invasive, multi-component liquid biopsy assay specifically designed for patients with urothelial carcinoma (including bladder cancer and upper tract urothelial carcinoma). It integrates multiple tumor-derived analytes from paired blood and urine samples: circulating cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) from peripheral blood plasma, urinary tumor DNA (utDNA)/cell-free DNA from urine, exosomal RNAs (e.g., miRNAs, lncRNAs) and proteins from urine-derived exosomes, and selected tumor-associated proteins. Serial sampling is performed at key clinical time points to enable longitudinal assessment: 1. Pre-diagnosis or baseline 2. During treatment 3. Post-treatment surveillance

Locations(1)

The second hospital of Tianjin Medical University

Tianjin, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07441499

Related Trials

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

NCT074135231 location

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT0727741310 locations

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

NCT074754031 location

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

NCT071802122 locations

The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer

NCT071305782 locations